Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
This article was originally published in The Pink Sheet Daily
Executive Summary
After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.
You may also be interested in...
Takeda’s Strategic Run Up To Nycomed
With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.
Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.
Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.